How to Start a Peptide Telehealth Business Legally (2026): Which Peptides Are Allowed

Status checked October 18, 2026. This is the fastest-moving area of compounding law this year; check the FDA links before you act.

Why peptides are complicated

A licensed 503A pharmacy can compound a drug for an individual patient only if its active ingredient meets one of three tests (21 U.S.C. 353a):

1. it has a USP monograph; or
2. it's a component of an FDA-approved drug; or
3. it's on FDA's 503A "bulks list," which FDA can only change by regulation after consulting its Pharmacy Compounding Advisory Committee (PCAC).

Most wellness peptides have no monograph and aren't part of any approved drug, so the bulks list is their only route (FDA briefing, July 2026). None of them is on it.

While it works through nominations, FDA uses an interim policy with three categories (FDA):

The last row trips people up. In 2026, many peptides left Category 2 because their nominations were withdrawn, not because FDA cleared them. They went to no category at all (FDA Law Blog).

The 2023–2026 timeline

A health-law firm expects the interim policy, if published, to be enforcement discretion for state-licensed 503A pharmacies only, with conditions such as informed consent and adverse-event reporting, and a permanent rule no earlier than 2027–2028 (Holland & Knight). Pharma groups have argued FDA can't allow compounding through an interim policy at all, so a legal challenge is possible.

Where each peptide stands (October 18, 2026)

Why "research peptides" are off limits

"Research use only" or "not for human consumption" labels don't protect a seller. In its August 2026 warning letters, FDA looked past the labels to the sites themselves: dosing instructions, reconstitution guides, peptide calculators and bacteriostatic water sold alongside. It treated the products as unapproved new drugs (FDA). LegitScript calls a prominent "not for human consumption" notice, "perhaps counterintuitively," a red flag (LegitScript).

State boards have gone further. Ohio's Board of Pharmacy and Alabama's medical board have both said clinics may not possess or dispense research-grade peptides (McDermott Will & Emery).

For a telehealth brand this is simple: never source from research suppliers, and don't let a partner do it for you. Any interim policy is expected to exclude research-chemical, supplement and 503B channels (Holland & Knight). LegitScript says working through a separate entity that dispenses non-permissible peptides "doesn't provide a workaround" (LegitScript).

Advertising peptides

• Meta and Google both require LegitScript certification before you can advertise prescription treatments, and neither allows unapproved substances (Meta, Google). See our LegitScript guide.
• A peptide becoming compoundable won't make it advertisable. Expect platforms and LegitScript to lag any FDA change, and keep unapproved compound names out of ads.
• Claims follow the FDA and FTC rules for compounded drugs. Don't say or imply a compounded peptide is FDA-approved, cleared or "fast-tracked," don't call it clinically proven, and make sure any health claim has competent and reliable scientific evidence behind it (FDA, FTC).

How to launch a compliant peptide telehealth brand

1. Build the menu from what's allowed today. That means approved drugs, components of approved drugs that aren't copies, and Category 1 substances. Put peptides under review on a waitlist page with no efficacy claims.
2. Contract a medical group with prescribers licensed in your launch states, either a clinician network's group or your own MSO and friendly PC.
3. Contract one or more 503A pharmacies licensed in every state you serve. Ask for certificates of analysis, sterility and endotoxin testing, and stability data for each peptide.
4. Design intake for real clinical judgment. FDA's September 2026 Empower letter criticized pre-selected menu options and justifications "repeated verbatim across many records" (FDA).
5. Put consent and safety reporting in place, including a clear statement that compounded drugs aren't FDA-approved and a path for adverse-event reports.
6. Have counsel review the site and ads, then apply for LegitScript before any paid acquisition.
7. Set a trigger for the interim policy. When it's published, check which peptides, routes, conditions and states it covers before adding anything.

The opportunity is real: search interest in starting a peptide business grew several-fold between late 2025 and mid 2026. The brands that last will be the ones that can take on newly allowed peptides the week the rules change, because their pharmacy, clinical process and claims are already compliant.

---